LSV Asset Management Sells 43,996 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

LSV Asset Management lessened its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 35.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 80,300 shares of the biotechnology company's stock after selling 43,996 shares during the period. LSV Asset Management's holdings in ADMA Biologics were worth $1,377,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in ADMA. Raymond James Financial Inc. acquired a new stake in ADMA Biologics in the 4th quarter worth $19,076,000. Renaissance Technologies LLC grew its position in ADMA Biologics by 2.8% during the fourth quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company's stock worth $64,654,000 after buying an additional 102,692 shares in the last quarter. Legal & General Group Plc increased its stake in ADMA Biologics by 20.1% during the fourth quarter. Legal & General Group Plc now owns 836,850 shares of the biotechnology company's stock valued at $14,352,000 after acquiring an additional 139,840 shares during the period. Envestnet Asset Management Inc. increased its stake in ADMA Biologics by 68.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 60,004 shares of the biotechnology company's stock valued at $1,029,000 after acquiring an additional 24,293 shares during the period. Finally, Aviva PLC acquired a new position in ADMA Biologics in the 4th quarter valued at approximately $539,000. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Price Performance

NASDAQ:ADMA traded up $0.08 during mid-day trading on Friday, hitting $21.31. The company's stock had a trading volume of 2,965,421 shares, compared to its average volume of 3,616,989. The company has a market capitalization of $5.04 billion, a price-to-earnings ratio of 76.11 and a beta of 0.53. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a fifty-two week low of $6.19 and a fifty-two week high of $23.64. The stock has a fifty day moving average of $18.26 and a 200-day moving average of $18.21.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.